NVG 333
Alternative Names: NVG-333Latest Information Update: 24 Jan 2023
At a glance
- Originator NovalGen
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 12 Jan 2023 Early research in Cancer in United Kingdom (Parenteral) before January 2023 (NovalGen pipeline, January 2023)